Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities:
Net (loss) income	$ (23,360)	$ 98,091
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Stock-based compensation	2,188	2,537
Foreign currency translation	6
Warrant liability revaluation gain	(361)	(6,983)
Series X preferred stock liability loss	2,400
Future tranche right liability revaluation gain		(118,803)
Issuance of common stock for services rendered	88	152
Accretion of discounts on short-term investments		(1)
Accretion of discounts on acquisition obligation	66
Depreciation and amortization expense	15	22
Deferred tax benefit	(6,318)
Changes in operating assets and liabilities, net of effects from Acquisition:
Accounts receivable	(2,294)
Prepaid expenses and other assets	506	2,134
Accounts payable, accrued expenses, and other liabilities	2,548	(1,751)
Other	21	5
Net cash used in operating activities	(24,495)	(24,597)
Cash Flows from Investing Activities:
Cash acquired in acquisition of Aceragen	5,482
Proceeds from maturity of available-for-sale securities		4,500
Net cash provided by investing activities	5,482	4,500
Cash Flows from Financing Activities:
Proceeds from common stock financings, net	(15)	19,518
Proceeds from employee stock purchases	49	59
Proceeds from exercise of common stock options and warrants	15	271
Payment on Acquisition Obligation	(1,534)
Payments on seller-financed purchases		(435)
Other	(3)
Net cash (used in) provided by financing activities	(1,488)	19,413
Net decrease in cash and cash equivalents	(20,501)	(684)
Cash and cash equivalent, beginning of period	32,545	33,229
Cash and cash equivalents, end of period	$ 12,044	32,545
Supplemental disclosure of cash flow information:
Cash paid for interest		5
Supplemental disclosure of non-cash financing and investing activities:
Offering costs in accrued expenses		3
Non-cash seller-financed purchases		$ 652